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Abstract: Background: The etiology of myeloproliferative neoplasms (MPN) (polycythemia 
vera; essential thrombocythemia; primary myelofibrosis) is unknown, however they are 
associated with a somatic mutation—JAK2 V617F—suggesting a potential role for 
environmental mutagens. Methods: We conducted a population-based case-control study in 
three rural Pennsylvania counties of persons born 1921–1968 and residing in the area 
between 2000–2008. Twenty seven MPN cases and 292 controls were recruited through 
random digit dialing. Subjects were genotyped and odds ratios estimated for a select set of 
polymorphisms in environmentally sensitive genes that might implicate specific 
environmental mutagens if found to be associated with a disease. Results: The presence of 
NAT2 slow acetylator genotype, and CYP1A2, GSTA1, and GSTM3 variants were 
associated with an average 3–5 fold increased risk. Conclusions: Exposures, such as to 
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aromatic compounds, whose toxicity is modified by genotypes associated with outcome in our 
analysis may play a role in the environmental etiology of MPNs. 
Keywords: case-control study; candidate gene; polycythemia vera (PV); essential 
thrombocythemia (ET); primary myelofibrosis (PMF); Mendelian randomization 
 
1. Introduction 
Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia 
(ET), and primary myelofibrosis (PMF), are rare cancers characterized by an overproduction of red 
blood cells and platelets [1]. Mandatory reporting on MPNs in the US began in 2001. The National Cancer 
Institute (NCI) estimated the incidence of PV, ET and PMF at 2.8, 1.5, and 0.4 cases per 100,000 person-
years for 2001–2004 [2]. In 2008 the World Health Organization (WHO) revised the diagnostic criterion 
to include a diagnostic algorithm with genetic information (JAK2 V617F) along with clinical 
information [3]. There are no known causes of MPNs although there have been a number of 
speculations about an environmental etiology [4]. 
The presence of the acquired JAK2 V617F somatic point mutation—a single-base substitution resulting 
in a change from valine to phenylalanine at position 617 in the protein on chromosome 9p [5]—is 
suspected to be pathognomonic of PV. It is present in nearly all PV patients (>95%), about half of those 
with ET or PMF, and less frequently in other hematologic diseases but not in any other cancers [6–8]. 
JAK2 is a protein that acts as an on-and-off switch regulating bone marrow activity [9]. In the presence 
of the mutation, a tyrosine kinase complex in bone marrow, normally responsible for regulating blood 
cell production, is activated to increase blood cell production [6]. The causes of the JAK2 V617F 
mutation are unknown [7]. 
There is strong evidence supporting familial risk for MPNs [4,10]. The role of inherited genetics 
has been suspected to influence MPN phenotype and susceptibility, including potential germ-line 
mutations yet to be identified [11]. Although functional genes that may modify the biological dose of a 
chemical mutagen have been studied for a wide range of cancers, no studies have investigated 
associations of these genotypes with MPNs [12]. Because of the role of the somatic JAK2 V617F 
mutation in the etiology of MPNs, genes that modify susceptibility to mutagenic chemicals are of 
particular interest. 
If we assume that there are genes that are not sufficient independent causes of MPNs but act 
exclusively to increase susceptibility to prevalent environmental mutagens, we can evaluate the main effect 
associations of these genes with MPNs to efficiently explore the potential role of the exposures whose 
effect they modify (i.e., under these assumptions genotype associations infer existence of the gene-
environment interactions) [13–15]. This approach is related to the Mendelian randomization that 
allows one to infer causation without directly measuring the exposure of interest by making the 
defensible assumption, in the given case, that genes are allocated independent of exposure and 
confounders [13]. The main objective of such analyses is not so much to quantify the extent of the 
gene-environment interaction but to use evidence of such interactions (assessed via genotype) to 
implicate specific exposures in the etiology of a disease. 
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The aim of the current analysis is thus to use this approach to identify potential classes of 
environmental exposures implicated in MPN etiology. 
2. Methods 
The study protocol was approved by the Drexel University and Geisinger Health Systems 
Institutional Review Boards. Participants received a $25 gift card for completing the phone survey phase 
and an additional $25 gift card if they gave a blood sample which was used in genotyping. 
2.1. Selection of Cases and Controls 
A case-control study was conducted in a tri-county area in Northeast Pennsylvania (Carbon, 
Luzerne, and Schuylkill counties) [16]. Cases and controls were eligible if they were born between 
1921 and 1968 (i.e., 42–89 years old at the time of the study), resided in the tri-county area between 
2000 and 2008 and completed a telephone survey. Cases were identified from the Pennsylvania Cancer 
Registry (PCR) using the International Classification of Diseases codes (ICD-O) for MPNs (codes for 
PV, M-9962/3; ETM, 9961/3; PMF, M-9931/3) as well as a PV cluster investigation in 2009 that 
included cases diagnosed between 2001 and 2006 in the three county area [17,18]. We included cases 
diagnosed up to 31 December 2010. We attempted to contact eligible cases that had relocated from the 
tri-county area. Controls were selected using a random digit dialing sample, stratified by age, sex and 
county to obtain distributions that reflected those of the source counties. Controls had to be free of 
MPNs during the time period that cases were ascertained. Among persons who consented to an 
interview, 57% of the cases and 62% of controls also provided DNA for the current analysis. Medical 
records of all cases not previously confirmed by the ATSDR cluster investigation [18] were evaluated 
by one of two expert panels (one created by the Pennsylvania Department of Health and one used in 
case ascertainment for a related study done by the University of Pittsburgh) [19]. Both panels used a 
similar methodology, and a two-thirds majority decision rule for case determination. Of the 31 cases 
genotyped and identified through the PCR and aforementioned ATSDR cluster investigation, 27 were 
confirmed as consistent with clinical records. These 27 cases of MPNs and 292 controls were eligible 
for the current analysis. 
2.2. Selection of Environmentally Sensitive Genes 
The National Institute of Environmental Health Sciences’ Environmental Genome Project (NIEHS 
EGP) has enumerated 647 known environmentally sensitive genes (ESG). We considered only genes 
identified by the NIEHS EGP that contained non-synonymous single nucleotide polymorphisms 
(nsSNPs), with a >5% minor allele frequency (MAF). Thus, 114 metabolism genes were given initial 
consideration, predominantly, the Phase I and Phase II detoxifying enzyme classes. The functional gene 
groups of interest regulate enzymes of two categories: metabolism or detoxification. Although other 
functional categories may be associated with the effect of chemicals of interest, they are out of the 
scope of this research. To facilitate the nsSNP selection, we used the Genome Variation Server (GVS) to 
obtain SNP information for nearly all EGP genes [20]. Only 82 of the 114 genes had coding SNP data 
in the GVS database. We reviewed the remaining 82 genes with nsSNP data for relevance to chemicals 
acting through a mutagenic pathway and the ability to be tested using the Illumina Bead Express 
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platform. We ultimately included 21 genes using this platform for this project, in addition to the three 
genes without coding data, as shown in Table 1. In general, the variants included in this analysis 
modify enzyme function to magnify the mutagenic effect of the xenobiotic substrate [21] and include 
variants of the following genes: AHR, ARNT, CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C9, 
CYP2E1, CYP3A5, CYP4B1, EPHX1, GSTA1, GSTP1, GSTM1, GSTM3, GSTT1, GSTZ1, MPO, NAT2, 
NQO1, OGG1, TP53 and XRCC1 (Table 1) [20,22]. A tag SNP rs1495741 was included for NAT2 and 
was used to infer NAT2 slow phenotype [23].  
Genotyping 
DNA was extracted from white blood cells by a standard salting-out protocol [24]. DNA quality 
was assessed by absorption at 260 and 280 nm. Samples were aliquoted into 96 well plates for 
analysis. Genotyping for all selected SNPs, except rs1048943 and rs4646903, was carried out using the 
Illumina Bead Express platform that employs VeraCode technology (Illumina, San Diego, CA, USA). 
Rs1048943 and rs4646903 were genotyped by TaqMan™ assays (LifeTechnologies/Applied 
Biosystems, Carlsbad, CA, USA) in a 384 well plate format using an Applied Biosystems 7900 PCR 
system. About 7% of samples were run in duplicate for both SNP genotyping assays. Deletions in 
GSTM1 and GSTT1 were determined using TaqMan Copy Number Assays™ with RNase P as the 
control gene. Samples were run in triplicate and CopyCaller™ Software was used for determination of 
the copy number. The bead express for the genotyping was run by Dr. Robin J. Leach, Co-Director of 
the Genomics Resource Core of the University of Texas, Health Services Center, School of Medicine, 
San Antonio. The JAK2 V617F testing was completed by Dr. Mingjiang Xu at Mt. Sinai School of 
Medicine.  
2.3. Statistical Analysis 
Descriptive analysis was conducted on the characteristics of the study population. Logistic 
regression estimated adjusted odds ratios (OR) and associated 95% confidence intervals (CI). All ORs 
were adjusted for the design variables used to stratify the population for selection of controls (sex, age, 
county).  
We used the highest frequency of the homozygous genotype as the reference unless the literature 
indicated a different referent group (see Table A1). We conducted analysis of genotypes in the control 
population to evaluate Hardy-Weinberg equilibrium in the genetic variants. We applied “gene-only 
analysis” [13] to estimate the main effect of the gene of interest as a signal for gene-environment 
interaction. Each genotype was tested one at a time. We also restricted analysis to only confirmed PV 
cases as well as only JAK2 V617F as additional case categories. In addition, an analysis that 
considered the total number of deleterious SNPs was also performed. Statistical analyses were 
conducted in SAS v. 9.2 (SAS Institute, Cary, NC, USA). 
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Table 1. Genes associated with a mutagenic chemical and minor allele frequency in the general population [19]. 
Genes Function and Variant Effects (GVS) Minor Allele Frequency (%) Chemical Exposure 
AHR 
This gene encodes a ligand-activated transcription factor involved in the 
regulation of biological responses to planar aromatic hydrocarbons. 
10 
2,3,7,8-TCDD, benzo[a]pyrene  
2,4'-DDT, Benzene 
ARNT The aryl hydrocarbon (Ah) receptor in xenobiotic Metabolism. 40 
Dioxin and polycyclic  
aromatic hydrocarbons 
CYP1A1 
CYP1A1 is also known as AHH (aryl hydrocarbon hydroxylase). It is involved 
in the metabolic activation of aromatic hydrocarbons (PAH) some of which are 
found in cigarette smoke. 
10 
2,3,7,8-TCDD, sodium  





The protein encoded by this gene localizes to the endoplasmic reticulum and its 
expression is induced by some PAHs, some of which are found in cigarette 
smoke. The enzyme’s endogenous substrate is unknown; however, it is able to 
metabolize some PAHs to carcinogenic intermediates. Other xenobiotic 
substrates for this enzyme include caffeine, aflatoxin B1, and acetaminophen. 
24 2,3,7,8-TCDD, benzo[a]pyrene 
CYP1B1 Metabolizes pro-carcinogens such as PAHs and 17beta-estradiol. 44 2,3,7,8-TCDD, benzo[a]pyrene 
CYP2B6 
This enzyme is known to metabolize some xenobiotics, such as the anti-cancer 
drugs cyclophosphamide and ifosphamide. 
21 2,4'-DDT 
CYP2E1 
Inactivates a number of drugs and xenobiotics and also bioactivates  
many xenobiotic substrates including ethanol to their hepatotoxic or 
carcinogenic forms. 
6 




In liver microsomes, this enzyme is involved in a NADPH-dependent transport 
pathway. It oxidizes a variety of structurally related compounds such as 
xenobiotics, fatty acids and steroids. 
31 
Drug metabolism and synthesis of 
cholesterol, steroids and other lipids 
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Table 1. Cont. 
Genes Function and Variant Effects (GVS) Minor Allele Frequency (%) Chemical Exposure 
CYP4B1 
Involved in metabolism of many xenobiotics including 2-aminofluorene, 
benzidine and 2-naphthylamine 
29 
Drug metabolism and synthesis of 
cholesterol, steroids and other lipids 
EPHX1 
Reduces enzyme function through metabolism of PAHs, and epoxide 
detoxification of 1,3-butadiene 
33 PAH, 1,3-butadiene 
GSTM1 
This GST family member is a polymorphic gene encoding proteins that are 
active in xenobiotic metabolism including carcinogens, environmental toxins 
and therapeutic drugs 
49 Styrene, benzene 
GSTA1 
This GST family member is a polymorphic gene encoding active, variant 
proteins that are thought to function in xenobiotic metabolism and in 
susceptibility to cancer 
14 Hetero-Cyclic Amine (HCA) 
GSTM3 
This GST family member is a polymorphic gene encoding proteins that are 
active in xenobiotic metabolism and in susceptibility to cancer 
32 PAH and HCA 
GSTP1 
This GST family member is a polymorphic gene encoding active, functionally 
different GSTP1 variant proteins that are thought to function in xenobiotic 
metabolism and play a role in vulnerability to cancer 
32 Benzene 
GSTT1 
This GST family member is a polymorphic gene with a role suspected in human 
carcinogenesis 
20 
Benzo[a]pyrene, methylene chloride, 
Styrene, Benzene 
GSTZ1 
This GST family member is a polymorphic gene that encodes multifunctional 
enzymes involved in the detoxification of some carcinogens, mutagens, and 
several therapeutic drugs 
5 Phenylalanine and tyrosine. 
MPO 
Xenobiotic metabolism and generates reactive oxygen species and can decrease 
normal enzyme function 
11 Benzene, BaP, HCA 
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Table 1. Cont. 
Genes Function and Variant Effects (GVS) Minor Allele Frequency (%) Chemical Exposure 
NAT2 
Polymorphisms in this gene are responsible for the N-acetylation polymorphism 
in which human populations segregate into rapid, intermediate, and slow 
acetylator phenotypes. Polymorphisms in this gene are also associated with 
higher incidences of cancer and drug toxicity. 
37 
Benzo[a]pyrene, arylamine and 
hydrazine metabolism 
NQO1 
Mutations in this gene have been associated with tardive dyskinesia (TD),  
an increased risk of hematotoxicity after exposure to benzene, and susceptibility 
to various forms of cancer. 
22 2,3,7,8-TCDD, benzo[a]pyrene 
OGG1 Can result in decreased base excision DNA repair. 22 
Aromatic hydrocarbons, most are 
repaired by NER not BER, this does 
repair 8-oxoG 
TP53 
Encodes a tumor suppressor protein and has an effect on cell-cycle regulation 
including DNA repair and changes in metabolism. 
39 All genotoxic compounds 
XRCC1 Involved in base excision repair and is linked to OGG1 gene. 12 Aromatic hydrocarbons 
 




The majority of MPN cases were confirmed to be primary PV (24/27). A greater proportion of cases 
were older (median age = 71 vs. 63 years.) and male (56% vs. 40%) compared to controls but 
otherwise were demographically similar (Table 2). The study population was entirely Caucasian with 
only two Latino controls. None of the cases and only six controls reported Jewish ancestry. All 
examined genes existed in Hardy Weinberg equilibrium (details not shown). The prevalence of CYP1A2, 
GSTA1, GSTM3, and NAT2 risk genotypes in controls were 7%, 18%, 9% and 57%, respectfully, 
which is in agreement with the reported frequency in the literature (Table 1). 
Table 2. Demographic characteristics of cases and controls. 
 
Variable 
All MPN Cases 
n = 27 (%) 
JAK2 V617F Positive 
Cases n = 22 (%) 
PV Cases  
n = 24 (%) 
Controls  
n = 292 (%) 
County     
Carbon 4 (15) 4 (18) 4 (17) 31 (11) 
Luzerne 12 (44) 10 (45) 10 (42) 177 (61) 
Schuylkill 11 (41) 8 (36) 10 (42) 84 (29) 
Age     
42–64 7 (26) 6 (27) 5 (21) 167 (57) 
65+ 20 (74) 16 (73) 19 (79) 125 (43) 
Sex (male) 15 (56) 12 (55) 13 (54) 118 (40) 
Race/ethnicity     
Non-Hisp. White 27 (100) 22 (100) 24 (100) 290 (99) 
Latino, Hispanic 0 0 0 2 (1) 
Marital status     
Married 18 (67) 15 (68) 15 (63) 183 (63) 
Widowed 7 (26) 5 (23) 7 (29) 47 (16) 
Currently single 2 (7) 2 (9) 2 (8) 62 (21) 
Education     
Less than high school 2 (7) 2 (9) 2 (8) 5 (2) 
High school/GED 13 (48) 11 (50) 13 (54) 106 (36) 
Some college 7 (26) 5 (23) 5 (21) 104 (36) 
Bachelors degree 2 (7) 2 (9) 2 (8) 36 (12) 
More than bachelors 3 (11) 2 (9) 2 (8) 41 (14) 
Household income     
Less than $20,000 3 (12) 3 (15) 3 (14) 38 (14) 
$20,000—$35,000 9 (36) 7 (35) 9 (41) 67 (24) 
$35,000—$50,000 2 (8) 2 (10) 2 (9) 54 (20) 
$50,000—$75,000 6 (24) 4 (20) 6 (27) 67 (24) 
More than $75,000 5 (20) 4 (20) 2 (9) 48 (18) 
Don’t know or refused to answer 2 2 2 18 
 
Results for associations of MPNs with the environmentally sensitive genes are summarized in  
Table 3. The crude estimates were very similar to the effect estimates adjusted for the design variables. 
It must be noted that all estimates of ORs had wide confidence intervals and any interpretation of the 
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magnitude of the effect and reliability of the hypothesis test should be approached with considerable 
caution. Having the most common homozygous CYP1A1 rs4646903, CYP1A2, EPHX1 rs2234922 and 
Tp53 alleles increased the odds of MPNs by four- to five-fold, with the point estimates of the odds 
ratios of 5.1, 4.1, 5.0, and 5.4, respectively. The CYP3A5 rs776746 AA genotype increased the risk of 
having an MPN on average 9-fold. The GSTA1 rs3957356 AA genotype was associated with an 
increase in effect estimates for any MPNs, with an average OR of 1.9. The GSTM3 rs7483 AA 
genotype was associated, on average, with elevated risk of any MPNs (OR = 3.9). The GSTM1 null 
and GSTZ1rs7972 AA genotypes followed a similar trend of doubling the odds of having an MPN, 
e.g., OR of 2.4 and 2.8, respectively. We found that the NAT2 slow acetylator AA genotype 
(rs1495741) was, on average, three times more common than wild-type genotype among cases, e.g., 
for any MPNs (OR = 3.1). We were not able to test for all seven of the other NAT2 SNPs shown in the 
literature to determine slow acetylator phenotype, but we were able to test for four of them. We 
observed a 2-fold increase for CYP2E1 across all case definitions. A similar increased risk was found 
for individuals with NQO1 rs1800566 AG (OR = 1.9) and a 3-fold increase for ARNT rs12410394 AG 
or GG genotypes with an OR of 3.2.  
Table 3. Association of myeloproliferative neoplasm with environmentally sensitive gene 
in case-control analysis: Odds ratios and (95% confidence intervals), adjusted for age, sex, 
and county 1. 
 
 
Gene 2 SNP 
At Risk Coding 
Sequence Variant 
All MPN Cases (n = 27) JAK2 V617F Cases (n = 22) PV Cases (n = 24) 
AHR rs2066853 AG 1.0 (0.4, 2.9) 1.3 (0.4, 3.8) 1.2 (0.4, 3.5) 
ARNT rs12410394 GG 0.4 (0.2, 1.0) 0.5 (0.2, 1.3) 0.4 (0.1, 1.0) 
  AA 0.2 (<0.1, 1.8) -- 0.2 (<0.1, 2.0) 
 rs12410394 AA 0.3 (<0.1, 2.4) -- 0.3 (<0.1, 2.8) 
 rs12410394 GG 0.5 (0.2, 1.2) 0.6 (0.2, 1.6) 0.4 (0.2, 1.2) 
  AG or GG 3.2 (0.4, 25.6) -- 2.9 (0.4, 23.3) 
CYP1A1 rs1048943 CT 2.1 (0.5, 8.1) 2.4 (0.6, 9.5) 1.4 (0.3, 7.0) 
 rs4646903 CC 5.1 (0.5, 57.5) -- 6.8 (0.6, 80.3) 
  CT 1.5 (0.6, 4.2) 1.6 (0.5, 4.6) 1.4 (0.5, 4.0) 
CYP1A2 rs762551 AA 0.8 (0.3, 1.7) 0.8 (0.3, 1.9) 0.8 (0.3, 1.9) 
  CC 4.1 (1.3, 13.2) 3.9 (1.1, 13.8) 3.7 (1.0, 13.3) 
CYP1B1 rs1056836 CC 1.9 (0.7, 5.4) 1.5 (0.5, 4.4) 1.5 (0.5, 4.5) 
  CG 0.7 (0.2, 1.8) 0.4 (0.1, 1.3) 0.6 (0.2, 1.6) 
CYP2B6 rs3745274 AC 1.1 (0.5, 2.6) 1.2 (0.5, 3.0) 1.3 (0.5, 3.2) 
CYP2C9 rs1057910 AC 1.4 (0.4, 4.5) 1.2 (0.3, 4.5) 1.6 (0.5, 5.3) 
 rs1799853 AG 0.9 (0.3, 2.5) 0.9 (0.3, 2.6) 0.6 (0.2, 1.9) 
CYP2E1 rs2031920 AG 2.0 (0.4, 9.8) 2.4 (0.5, 12.3) 2.3 (0.4, 11.7) 
 rs2070673 AT 0.7 (0.2, 2.0) 0.7 (0.2, 2.1) 0.6 (0.2, 1.9) 
 rs6413432 AT 1.5 (0.6, 4.2) 2.0 (0.7, 5.6) 1.8 (0.6, 5.0) 
CYP3A5 rs776746 AA 9.1 (0.5, 162.6) 11.0 (0.6, 200.1) 10.7 (0.6, 192.5) 
  AG 0.9 (0.3, 3.4) 0.7 (0.2, 3.4) 1.1 (0.3, 4.2) 
CYP4B1 rs2297810 AG 1.3 (0.5, 3.0) 1.2 (0.5, 3.1) 1.5 (0.6, 3.7) 
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Table 3. Cont. 
Gene 2 SNP 
At Risk Coding 
Sequence Variant 
All MPN Cases (n = 27) JAK2 V617F Cases (n = 22) PV Cases (n = 24) 
EPHX1 rs1051740 GG 2.3 (0.6, 8.4) 2.4 (0.6, 8.9) 2.3 (0.6, 8.8) 
  AG 1.6 (0.6, 3.9) 1.0 (0.4, 2.8) 1.3 (0.5, 3.2) 
 rs2234922 GG 5.0 (0.7, 34.1) 3.7 (0.3, 39.9) 6.4 (0.9, 46.7) 
  AG 0.9 (0.3, 2.2) 0.9 (0.3, 2.4) 1.0 (0.4, 2.7) 
GSTA1 rs3957356 AA 1.9 (0.8, 4.7) 2.7 (1.0, 7.0) 2.3 (0.9, 5.9) 
GSTM1 Null   2.4 (1.0, 5.9) 2.2 (0.8, 6.0) 2.5 (0.9, 6.5) 
GSTM3 rs7483 AA 3.9 (1.2, 12.3) 4.5 (1.2, 16.0) 3.3 (1.0, 11.2) 
  AG 1.2 (0.5, 3.1) 1.6 (0.6, 4.5) 1.0 (0.4, 2.6) 
 rs1332018 CC 0.8 (0.3, 2.2) 0.6 (0.2, 2.1) 1.0 (0.3, 3.0) 
  AC 0.2 (0.1, 0.7) 0.3 (0.1, 0.7) 0.3 (0.1, 0.9) 
 rs1799735 TG 0.5 (0.2, 1.4) 0.4 (0.1, 1.6) 0.6 (0.2, 1.7) 
GSTM3 rs7483 AA 3.5 (1.2, 10.0) 3.5 (1.1, 10.7) 3.3 (1.1, 10.3) 
GSTP1 rs1695 AG 0.8 (0.4, 1.9) 0.7 (0.3, 1.8) 0.7 (0.3, 1.8) 
 rs1138272 AA 1.2 (0.4, 4.0) 1.1 (0.3, 4.0) 1.0 (0.3, 3.8) 
  AG 0.4 (<0.1, 2.9) -- 0.4 (0.0, 3.2) 
GSTT1 Null   0.8 (0.3, 2.5) 0.5 (0.1, 2.1) 0.6 (0.2, 2.4) 
GSTZ1 rs7972 AA 2.8 (0.3, 28.7) 4.0 (0.4, 41.2) 3.4 (0.3, 37.3) 
  AG 1.4 (0.5, 3.9) 1.8 (0.6, 5.3) 1.6 (0.5, 4.8) 
 rs1046428 AG 0.4 (0.2, 1.1) 0.3 (0.1, 1.0) 0.4 (0.1, 1.1) 
NAT2 rs1041983 AA 0.6 (0.1, 2.5) 0.7 (0.1, 3.1) 0.3 (<0.1, 2.2) 
 rs1495741 AA 3.1 (1.1, 8.7) 4.6 (1.3, 16.1) 3.5 (1.1, 10.8) 
 rs1799929 AA 2.4 (1.0, 5.7) 3.4 (1.3, 8.4) 2.4 (1.0, 6.1) 
 rs1799930 AA 0.3 (<0.1, 2.6) 0.4 (<0.1, 3.1) -- 
 rs1801280 GG 2.8 (1.2, 6.5) 4.0 (1.6, 9.9) 2.9 (1.2, 7.1) 
NQO1 rs1131341 AG 1.7 (0.4, 6.6) 2.3 (0.6, 8.8) 1.2 (0.2, 5.6) 
 rs1800566 AA 1.6 (0.2, 14.4) -- 2.0 (0.2, 17.9) 
  AG 1.9 (0.8, 4.3) 1.8 (0.7, 4.4) 1.7 (0.7, 4.1) 
OGG1 rs1052133 CG 1.0 (0.4, 2.4) 0.9 (0.4, 2.4) 1.0 (0.4, 2.6) 
  GG 0.6 (0.1, 4.7) 0.7 (0.1, 5.6) 0.6 (0.1, 5.3) 
Tp53 rs1042522 GG 5.4 (1.4, 20.8) 8.0 (2.0, 33.0) 6.8 (1.7, 28) 
  CG 1.0 (0.4, 42.3) 1.3 (0.5, 3.4) 1.0 (0.4, 2.6) 
XRCC1 rs25487 AA 0.9 (0.3, 2.6) 1.4 (0.4, 5.0) 1.1 (0.3, 3.8) 
  AG 0.5 (0.2, 1.3) 0.8 (0.3, 2.1) 0.5 (0.2, 1.4) 
 rs25489  GG 0.8 (<0.1) 0.8 (<0.1) 0.7 (<0.1) 
 rs1799782 AA 18.2 (1.0, 339) - - 
  AG 1.6 (0.4, 6.1) 1.3 (0.3, 6.2) 1.1 (0.2, 5.3) 
 
1 Odds ratios could not be calculated because there were no cases/controls with those variants for missing 
results and specifically, MPO rs2333277 genotype CC and XRCCI, rs25489 AG genotypes had no cases with 
any case definition; 2 Susceptible genes to mutagenic chemicals and Single Nucleotide Polymorphisms 
(SNPs) with rs number. 
All but one case (97%) harbored at least two of the evaluated SNPs that signal association of the 
outcomes with exposure to xenobiotics (AHR, CYP1E2, GSTM1, Tp53, GSTT1, GSTM3, CYP1A2, 
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NAT2, or GSTA1 30/31) compared to 63% of controls (Table 4). None of the results, either for 
individual genotype or presence of two or more of these SNPs varied materially in analyses restricted 
to only PV cases or to cases with confirmed JAK2 somatic mutations.  
Table 4. Total number deleterious genes, number and frequency for cases and controls. 
Number of Deleterious Genes 1 Number and Frequency Deleterious Genes 1 Frequency Deleterious Genes 1 
 Cases Controls Cases (%) Controls (%) 
0 0 11 0 3.70 
1 1 99 3.23 33.30 
At least 2 30 182 96.78 63.00 
1 AHR, CY1A2, CY1E2, GSTA1, GSTM1, GSTM3, GSTT1, NAT2, TP53. 
4. Discussion 
After studying the main effects of 24 environmentally sensitive genes, we found that variants in 
NAT2, CYP1A2, GSTA1, and GSTM3 were statistically significantly associated with MPN risk with 
ORs between 1.5 and 4. In addition, variants in CYPA1, CYP2E1, CYP3A5, EPHX1, TP53, MPO, 
GSTZ1, ARNT, and NQO1 were associated with MPNs in this study with ORs between 1.4 and 9. 
While these results do not confirm gene-environment interaction for any one specific chemical, the 
findings encourage further explanation of the interaction hypothesis with respect to biological 
pathways and chemical exposures implicated by these genes. These same genes appear to be associated 
with the presence of the JAK2 V617F mutation that is pathogenomic of MPNs. 
To detect the potential for existence of gene-environment interactions, the main effects of genes were 
used in this analysis. We did not have measures of the exposures of interest available and therefore could 
not estimate interactions or stratified effects directly. If we assume that genes alone do not cause MPNs, but 
can only act by modifying the toxicity of an environmental exposure, then testing the main effect of the 
genes is an efficient way to generate evidence supporting qualitative gene-environment interaction [13,14].  
Based on this reasoning, we are essentially assuming the existence of gene-environment interaction 
without an independent gene effect. A main gene effect without exposure is unlikely, based on the 
knowledge about the pathway for these diseases [6,7]. Therefore we have no reason to believe that 
MPNs are caused exclusively by the genotypes under investigation. 
In our study sample, we did not find any associations with smoking or occupational exposure to 
polycyclic aromatic hydrocarbons with risk of developing an MPN [16]. However, perhaps 
paradoxically, our findings suggest that specific genotypes that modify the toxicity of these exposures 
may play a role in MPNs. The lack of an association of smoking with MPNs is consistent with the 
limited prior literature [4]. However, the existing literature on occupational and chemical exposures and 
MPN is neither specific, nor consistent [25–29].  
Moore et al., reported an association of bladder cancer with NAT2 slow acetylator genotype and 
smoking intensity [30]. Since aromatic amines are detoxified by NAT2, interaction is biologically 
plausible. Thus, if carcinogens in tobacco smoke where implicated in MPNs, as they are in bladder 
cancer, then we should have detected the main effect of NAT2 in our study. However, absence of an 
effect from smoking per se suggests that compounds not important to the toxicity of tobacco smoke 
but affected by NAT2 should be scrutinized. 
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Functional SNPs associated with benzene exposure were also explored in this analysis: CYP2E1, 
GSTM1, AHR, and GSTT1 variants modify the biological dose of benzene. In addition, Tp53 has been 
reported to be involved with benzene hematopoietic stem-cell toxicity in mice [31]. Effect estimates 
for AHR and GSTT1 were essentially null but not for GSTM1 and Tp53. Work by Quiroga, Kaplan et 
al., and Mele et al., implicated benzene or petroleum products as risk factors [25,32,33]. Among 
analyses with the best available estimates of exposure to benzene, a pooled analysis of 29 cases of 
myelodysplastic syndrome (MDS), showed a monotonic-dose response relationship with cumulative 
exposure to benzene (odds ratio (OR) = 4.33 95% CI: 1.31, 14.3) but not for other subtypes including 
30 myeloproliferative disease (MPD) cases (OR = 1.79, 95% CI: 0.68, 4.74) [29]. Work of Schnatter et 
al. implies that diagnostic heterogeneity may be complicating attribution to specific MPNs to 
environmental exposures [29]. Overall, our results are consistent with the supporting prior body of 
literature that suggests that benzene may be implicated in some MPNs, although clearly the evidence is 
far from being consistent and conclusive.  
Our study was limited by the small number of cases. MPNs are rare hematological malignancies  
with only a limited number of cases available for recruitment—even under cluster outbreak conditions. 
Our study is most informative about PV cases only. We included a total of 24 PV cases, which is in the 
range of other studies of MPN etiology with case groups ranging from 10 to 133 [32,33] (see also  
n = 53 [31] and n = 30 [29]). Another limitation could be an unbalance in age and sex distribution of cases 
and controls. We attempted to control this by including these factors in the logistic regression. But 
residual confounding cannot be ruled out. 
Although MPNs are classified at malignant, they became a reportable disease in the US only 
recently, in 2001, and in Pennsylvania only hospitals were able to report until recently, so there is the 
possibility of under-reporting of these MPNs to the cancer registry. There were also changes in the 
diagnostic criteria by the WHO in 2001 and again in 2008 [34]. The 2008 diagnostic criteria included 
molecular as well as histological information for diagnosis, including the JAK2 V617F mutation [34]. 
Our ability to test for this mutation directly helped minimize outcome misclassification. Furthermore, 
by considering only individuals with JAK2 mutation to be cases in some of our analyses, we reduced 
the possibly of outcome misclassification if one were to assume that persons with the mutation 
experience exposures that already placed them on pathway towards developing clinical MPN. 
The misclassification of genotypes was not a concern in this study because our call rate was high 
(>95%), and we only had one SNP (UGT1A) that consistently did not perform well [35,36]. Our study 
is vulnerable to false positive discovery due to “multiple comparisons” [37]. However, unlike GWAS 
studies, we started with 648 genes of interest and only examined genes that met our a priori “plausible 
candidate”. Our selective genotypes were functional SNPs which directly affect the enzymatic activity 
of the gene, influencing biological pathways that affect metabolic activation or detoxification 
processes of metabolism for mutagenic chemicals. We did not correct for elevated type II error 
associations in applying a correction factor in the analysis.  
5. Conclusions 
Our research made two main pivotal assumptions. First, we assumed that genotype and 
environmental exposures in this study population are independent. Second, we assumed that disease 
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risk will not vary with genotype for subjects without environmental exposure. From this, we exploit 
the most generic form of Mendelian randomization that individuals receive a random allocation of 
alleles from their parents. Gustasfon and Burstyn presented this method and concluded that when both 
of these assumptions are met, using data on genotype and disease jointly, with only knowledge of the 
prevalence of exposure without individual level data on exposure, can be a practical approach to 
investigate gene-environment interaction [14]. Through this approach, a signal of increased risk will 
only result if an environmental exposure is operating through gene-environment interaction [27]. Our 
findings therefore suggest that aromatic compounds and heterocyclic amines play a role in MPNs. 
Future research on the exposures (other than smoking) affected by the NAT2, GST, and CYP genes may 
be fruitful avenues to better evaluate the environmental etiology of MPNs.  
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Appendix 
Table A1. The Distribution of Variants of Environmentally Sensitive Genes in the Study 
Sample; Reference Group Identified by an asterix (*). 
Susceptible Genotype SNP 
and rs Number 1 
All MPN Cases 2 
n = 27 (%) 
JAK2 V617F Cases 2 
n = 22 (%) 
PV Cases 2  
n = 24 (%) 
Controls  
n = 292 (%) 
AHR rs2066853     
AG 5 (19) 5 (23) 5 (21) 59 (20) 
AA 0 0 0 1 (0 ) 
GG * 22 (81) 17 (77) 19 (79) 230 (79) 
Missing 0 0 0 2 
ARNT rs12410394     
AA 1 (4) 0 1 (4) 33 (11) 
AG * 19 (70) 15 (68) 17 (71) 135 (47) 
GG * 7 (26) 7 (32) 6 (25) 122 (42) 
Missing 0 0 0 2 
CYP1A2 rs762551     
AA* 11 (41) 9 (41) 10 (42) 145 (50) 
AC* 11 (41) 9 (41) 10 (42) 128 (44) 
CC 5 (19) 4 (18) 4 (17) 19 (7) 
CYP1B1 rs1056836     
CC 9 (33) 7 (32) 7 (29) 52 (18) 
CG 9 (33) 6 (27) 8 (33) 148 (51) 
GG * 9 (33) 9 (41) 9 (38) 91 (31) 
Missing 0 0 0 1 
CYP2B6 rs3745274     
AC 17 (63) 14 (64) 16 (67) 164 (56) 
AA * 10 (37) 8 (36) 8 (33) 128 (44) 
CYP2C9 rs1057910     
AC 4 (15) 3 (14) 4 (17) 32 (11) 
AA * 23 (85) 19 (86) 20 (83) 257 (89) 
Missing 0 0 0 3 
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Table A1. Cont. 
Susceptible Genotype SNP 
and rs Number 1 
All MPN Cases 2 
n = 27 (%) 
JAK2 V617F Cases 2 
n = 22 (%) 
PV Cases 2  
n = 24 (%) 
Controls  
n = 292 (%) 
rs1799853     
AG 6 (22) 5 (23) 4 (17) 64 (22) 
GG * 21 (78) 17 (77) 20 (83) 225 (78) 
Missing 0 0 0 3 
CYP2E1 rs2031920     
AG 2 (7) 2 (9) 2 (8) 12 (4) 
GG * 25 (93) 20 (91) 22 (92) 275 (96) 
Missing 0 0 0 5 
rs2070673     
AT 5 (19) 4 (18) 4 (17) 74 (26) 
AA 0 0 0 9 (3) 
TT * 22 (81) 18 (82) 20 (83) 206 (71) 
Missing 0 0 0 3 
rs6413432     
AT 6 (22) 6 (27) 6 (25) 48 (17) 
TT 0 0 0 2 (1) 
AA * 21 (78) 16 (73) 18 (75) 240 (83) 
Missing 0 0 0 2 
CYP3A4 rs2740574     
AG 0 0 0 14 (5) 
AA * 26 (100) 22 (100) 23 (100) 277 (95) 
Missing 1 0 1 1 
CYP3A5 rs776746     
AA 1 (4) 1 (5) 1 (4) 1 (0) 
AG 3 (11) 2 (9) 3 (13) 38 (13) 
GG * 23 (85) 19 (86) 20 (83) 252 (87) 
Missing 0 0 0 1 
CYP4B1 rs2297810     
AG 9 (33) 7 (32) 9 (38) 74 (26) 
AA 0 0 0 3 (1) 
GG * 18 (67) 15 (68) 15 (63) 212 (73) 
Missing 0 0 0 3 
EHPX1 rs1051740     
GG 4( 15) 4 (18) 4 (17) 27 (9) 
AG 14 (52) 9 (41) 11 (46) 131 (45) 
AA * 9 (33) 9 (41) 9 (38) 131 (45) 
Missing 0 0 0 3 
rs2234922     
GG 2 (7) 1 (5) 2 (8) 4 (1) 
AG 7 (26) 6 (27) 7 (29) 85 (29) 
AA * 18 (67) 15 (68) 15 (63) 200 (69) 
Missing 0 0 0 3 
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Table A1. Cont. 
Susceptible Genotype SNP 
and rs Number 1 
All MPN Cases 2 
n = 27 (%) 
JAK2 V617F Cases 2 
n = 22 (%) 
PV Cases 2  
n = 24 (%) 
Controls  
n = 292 (%) 
GSTA1 rs3957356     
AA * 9 (33) 9 (41) 9 (38) 53 (18) 
AG * 11 (41) 7 (32) 9 (38) 148 (51) 
GG 7 26 6 (27 6 (25) 91 (31) 
GSTM1     
Undetermined 0 0 0 1 (0) 
0 20 (74) 16 (73) 18 (75) 155 (53) 
1 * 7 (26) 6 (27) 6 (25) 116 (40) 
2 * 0 0 0 20 (7) 
GSTM3 rs7483     
AA 6 (22) 5 (23) 5 (21) 26 (9) 
AG 11 (41) 10 (45) 9 (38) 124 (43) 
GG * 10 (37) 7 (32) 10 (42) 137 (48) 
Missing 0 0 0 5 
rs1332018     
CC 7 (26) 5 (23) 7 (29) 45 (16) 
AC 7 (26) 6 (27) 7 (29) 156 (54) 
AA * 13 (48) 11 (50) 10 (42) 89 (31) 
Missing 0 0 0 2 
rs1799735     
TG 4 (15) 3 (14) 4 (17) 81 (28) 
TT 0 0 0 8 (3) 
GG * 23 (85) 19 (86) 20 (83) 200 (69) 
Missing 0 0 0 3 
GSTP1 rs1695     
     
AG 13 (48) 10 (45) 11 (46) 135 (47) 
GG 0 0 0 33 (11) 
AA * 14 (52) 12 (55) 13 (54) 122 (42) 
Missing 0 0 0 2 
rs1138272     
AA 4 (15) 3 (14) 3 (13 (35 12) 
AG 1 (4) 0 1 (4 ) 30 (10) 
GG * 22 (81) 19 (86) 20 (83) 227 78 
GSTT1     
3 * 0 0 0 1 (0) 
Undetermined 0 0 0 1 (0) 
0 4 (15) 2 (9) 3 (13) 46 (16) 
1 * 22 (81) 20 (91) 21 (88) 197 (67) 
2 * 1 (4) 0 0 47 (16) 
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Table A1. Cont. 
Susceptible Genotype SNP 
and rs Number 1 
All MPN Cases 2 
n = 27 (%) 
JAK2 V617F Cases 2 
n = 22 (%) 
PV Cases 2  
n = 24 (%) 
Controls  
n = 292 (%) 
GSTZ1 rs7972     
AA 1 (4) 1 (5) 1 (4) 6 (2) 
AG 5 (19) 5 (23) 5 (21) 44 (15) 
GG * 21 (78) 16 (73) 18 (75) 242 (83) 
rs1046428     
AG 6 (23) 4 (19) 5 (22) 98 (34) 
AA 0 0 0 9 (3) 
GG * 20 (77) 17 (81) 18 (78) 184 (63) 
Missing 1 1 1 1 
MPO rs2333277     
CC 0 0 0 1 (0.3) 
AA * 27 (100) 22 (100) 24 (100) 289 (99) 
Missing 0 0 0 2 
NAT2 rs1041983     
GG * 13 (48) 12 (55) 12 (50) 140 (48) 
AG * 12 (44) 8 (36) 11 (46) 116 (40) 
AA 2 (7) 2 (9) 1 (4) 35 (12) 
Missing 0 0 0 1 
rs1495741     
GG 1 (4) 1 (5) 1 (4) 22 (8) 
AG 4 (15) 2 (9) 3 (13) 104 (36) 
AA * 22 (81) 19 (86) 20 (83) 164 (57) 
Missing 0 0 0 2 
rs1799929     
GG* 9 (33) 7 (32) 7 (29) 112 (38) 
AG* 8 (30) 5 (23) 8 (33) 124 (42) 
AA 10 (37) 10 (45) 9 (38) 56 (19) 
rs1799930     
GG * 14 (52) 13 (59) 13 (54) 148 (51) 
AG * 12 (44) 8 (36) 11 (46) 114 (39) 
AA 1 (4) 1 (5) 0 29 (10) 
Missing 0 0 0 1 
rs1801279     
GG * 27 (100) 22 (100) 24 (100) 291 (100) 
AG * or AA     
Missing 0 0 0 1 
rs1801280     
GG * 11 (41) 11 (50) 10 (42) 58 (20) 
AG * 9 (33) 6 (27) 9 (38) 127 (44) 
AA 7 (26) 5 (23) 5 (21) 106 (36) 
Missing 0 0 0 1 
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Table A1. Cont. 
Susceptible Genotype SNP 
and rs Number 1 
All MPN Cases 2 
n = 27 (%) 
JAK2 V617F Cases 2 
n = 22 (%) 
PV Cases 2  
n = 24 (%) 
Controls  
n = 292 (%) 
NQO1     
rs1131341     
AG 3 (11) 3 (14) 2 (8) 17 (6) 
GG * 24 (89) 19 (86) 22 (92) 275 (94) 
rs1800566     
AA 1 (4) 0 1 (4) 12 (4) 
AG 12 (44) 10 (45) 10 (42) 87 (30) 
GG * 14 (52) 12 (55) 13 (54) 193 (66) 
CYP1A1 rs1048943     
CT 3 (12) 3 (14) 2 (9) 18 (6) 
TT * 23 (88) 19 (86) 21 (91) 269 (94) 
Missing 1 0 1 5 
rs4646903     
CC 1 (4) 0 1 (4) 3 (1) 
CT 6 (23) 5 (24) 5 (22) 46 (16) 
TT * 19 (73) 16 (76) 17 (74) 239 (83) 
Missing 1 1 1 4 
Tp53 rs1042522     
GG 4 (15) 4 (18) 4 (17) 12 (4) 
CG 10 (37) 9 (41) 9 (38) 117 (40) 
CC * 13 (48) 9 (41) 11 (46) 160 (55) 
XRCC1 rs25489     
AG 27 (100) 22 (100) 24 (100) 239 (84) 
GG 0 0 0 7 (2) 
AA * 0 0 0 37 (13) 
Missing 0 0 0 9 
rs1799782     
AA 3 (11) 2 (9) 2 (8) 1 (0.3) 
AG 1 (4) 0 0 23 (7) 
GG * 23 (85) 20 (91) 22 (92) 267 (91) 
Missing 0 0 0 1 
rs25487     
AA 4 (15) 4 (18) 4 (17) 42 (14) 
AG 9 (33) 9 (41) 8 (33) 125 (43) 
GG * 14 (52) 9 (41) 12 (50) 120 (41) 
Missing 0 0 0 5 
1. Susceptible genes to mutagenic chemicals and Single Nucleotide Polymorphisms (SNPs) with rs number;  
2. All MPN cases include PV, ET and PMF, confirmed cases by expert panel, confirmed JAK2 V617F 
mutation with PV, ET or PMF confirmed by expert panel, confirmed by expert panel PV cases only. 
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